[HTML][HTML] Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease
KM Ashe, E Budman, DS Bangari, CS Siegel… - Molecular …, 2015 - Springer
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
[HTML][HTML] Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
KM Ashe, E Budman, DS Bangari, CS Siegel… - Molecular …, 2015 - ncbi.nlm.nih.gov
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
KM Ashe, E Budman, DS Bangari… - Molecular …, 2015 - search.ebscohost.com
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
KM Ashe, E Budman, DS Bangari… - Molecular Medicine …, 2015 - europepmc.org
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
KM Ashe, E Budman, DS Bangari… - Molecular …, 2015 - pubmed.ncbi.nlm.nih.gov
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
[HTML][HTML] Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
KM Ashe, E Budman, DS Bangari… - Molecular …, 2015 - molmed.biomedcentral.com
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
KM Ashe, E Budman, DS Bangari… - Molecular …, 2015 - search.proquest.com
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
[PDF][PDF] Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry
KM Ashe, E Budman, DS Bangari… - MOL …, 2015 - molmed.biomedcentral.com
Fabry disease is an X-linked inherited metabolic disorder caused by the deficient activity of
the lysosomal hydrolase a-galactosidase A (a-Gal A)(1). Progressive lysosomal …
the lysosomal hydrolase a-galactosidase A (a-Gal A)(1). Progressive lysosomal …
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
KM Ashe, E Budman, DS Bangari… - Molecular Medicine …, 2015 - europepmc.org
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …
activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various …